PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8273368-4	1993	Other combinations of IFN-alpha with standard therapies and/or experimental therapies (Pentostatin) seem to contribute-according to preliminary data-to an improvement of remission rates in CTCL.	Pentostatin	87-98	interferon alpha 1	Homo sapiens	22-31	
9001417-1	1997	The long-term outcome of patients with hairy cell leukemia resistant to interferon-alpha (IFN-alpha) following treatment with deoxycoformycin (DCF) was examined, and the kinetics of recovery of lymphocyte subsets and factors influencing the rate of recovery investigated.	Pentostatin	126-141	interferon alpha 1	Homo sapiens	90-99	
7820042-3	1994	In this paper, we report our experience with dCF in a series of 38 HCL patients who had progression of their disease after IFN therapy.	Pentostatin	45-48	interferon alpha 1	Homo sapiens	123-126	
2273300-4	1990	If OAS and ADA are important in the antitumor effects of IFN and DCF, our results suggest that combination therapy with IFN and DCF could be counterproductive.	Pentostatin	65-68	interferon alpha 1	Homo sapiens	120-123	
2273300-4	1990	If OAS and ADA are important in the antitumor effects of IFN and DCF, our results suggest that combination therapy with IFN and DCF could be counterproductive.	Pentostatin	128-131	interferon alpha 1	Homo sapiens	57-60	
27463984-11	1990	A group of 12 patients who had received alpha-IFN immediately prior to treatment with DCF and had obtained clinical and haematological benefit had fewer infections with DCF than the group who had either not received IFN immediately before or who had failed to respond to it.	Pentostatin	86-89	interferon alpha 1	Homo sapiens	46-49	
27463984-11	1990	A group of 12 patients who had received alpha-IFN immediately prior to treatment with DCF and had obtained clinical and haematological benefit had fewer infections with DCF than the group who had either not received IFN immediately before or who had failed to respond to it.	Pentostatin	169-172	interferon alpha 1	Homo sapiens	46-49	
2583256-2	1989	Anecdotal reports have suggested that patients who failed IFN could achieve durable responses with dCF, although the frequency with which this was said to have occurred was unknown.	Pentostatin	99-102	interferon alpha 1	Homo sapiens	58-61	
2583256-3	1989	We reviewed the available data on the responsiveness of HCL to dCF after IFN therapy by analyzing cases reported in the literature and those treated under the Special Exception mechanism of the National Cancer Institute, Division of Cancer Treatment.	Pentostatin	63-66	interferon alpha 1	Homo sapiens	73-76	
2583256-6	1989	dCF is an active agent in HCL both as initial therapy and for the salvage of patients who have failed IFN.	Pentostatin	0-3	interferon alpha 1	Homo sapiens	102-105	
2789273-3	1989	In this phase II study of the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC), the efficacy and toxicity of DCF were investigated in patients who were resistant to IFN-a treatment.	Pentostatin	161-164	interferon alpha 1	Homo sapiens	217-222	
2789273-16	1989	Thus, DCF is highly active in patients with HCL resistant to IFN-a.	Pentostatin	6-9	interferon alpha 1	Homo sapiens	61-66